What Newsmax Inc. told the SEC could break it.

Newsmax Media's advertising revenue largely depends on audience measurement, which is difficult to measure: Nielsen's statistical sampling method is the primary measurement methodology used for its linear-television advertising sales, so if measurement methodologies do not accurately reflect actual viewership (or if Nielsen changes its methodology or the company is undermeasured), its advertising sales and revenue could be negatively affected.

“Although Nielsen's statistical sampling method is the primary measurement methodology used for Newsmax Media's linear television advertising sales, Newsm”

Newsmax has incurred losses in prior periods, may not be profitable in the future, and its plans to maintain and increase liquidity may not succeed; its ability to achieve profitability depends on generating and sustaining substantially increased revenues amid the difficulties facing the television/media industry, and it may continue to incur operating losses as it executes its growth strategy — so a failure to grow revenue sufficiently would pressure its liquidity and going-concern position.

“We have incurred losses in prior periods, may not be profitable in the future, and our plans to maintain and increase liquidity may not be successful. Our ability to achieve profitability will depend upon our ability to generate and sustain substantially increased revenues.”

Newsmax faces material defamation-litigation exposure tied to its news content: it agreed to a settlement of approximately $40.0 million (payable over time, plus a five-year warrant later convertible into 1,333,333 Class B shares) to resolve litigation with Smartmatic, and as a political news broadcaster it remains exposed to further defamation, election-related or other content-based claims that could result in significant damages, settlements and legal costs and harm its reputation and financial condition.

“The Company agreed to pay a settlement of approximately $40.0 million payable over time and granted a five year warrant to purchase 2,000 shares of Series B preferred stock at an exercise price of $5,000 per share.”

Newsmax's Medix Select business sells dietary supplements (marketed for benefits such as pain, blood glucose, heart health, energy and wellness) manufactured at third-party FDA-registered facilities meeting current Good Manufacturing Practices standards; this exposes it to FDA and FTC regulation of supplement manufacturing quality and of health-benefit/marketing claims, where adverse findings, claim-substantiation challenges, recalls or third-party-manufacturer compliance failures could disrupt the product line and create liability.

“All Medix Select supplements are manufactured at third-party manufacturing facilities that are U.S. Food and Drug Administration (“FDA”) registered and meet current Good Manufacturing Practices standards.”